Bank Of America Corp Tricida, Inc. Transaction History

Bank Of America Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	BUY	$0.14 - $12.49 $8,138 - $726,043	58,130 Added 333.7%	75,550 $11,000
Q3 2022 Nov 14, 2022	BUY	$8.51 - $13.6 $47,553 - $75,996	5,588 Added 47.23%	17,420 $183,000
Q2 2022 Aug 12, 2022	BUY	$7.31 - $11.85 $32,397 - $52,519	4,432 Added 59.89%	11,832 $114,000
Q1 2022 May 16, 2022	BUY	$7.35 - $10.63 $40,461 - $58,518	5,505 Added 290.5%	7,400 $61,000
Q4 2021 Feb 08, 2022	SELL	$4.19 - $9.56 $740,871 - $1.69 Million	-176,819 Reduced 98.94%	1,895 $18,000

Q3 2021 Nov 15, 2021	SELL	$3.56 - $4.64 $99,658 - $129,892	-27,994 Reduced 13.54%	178,714 $830,000
Q2 2021 Sep 13, 2021	BUY	$3.95 - $5.41 $816,496 - $1.12 Million	206,708 New	206,708 $893,000

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.